Literature DB >> 23816973

Clinicians' attitudes toward general screening of the Ashkenazi-Jewish population for prevalent founder BRCA1/2 and LRRK2 mutations.

S Shkedi-Rafid1, G Ofer-Bialer, V Meiner, R Calderon-Margalit.   

Abstract

AIMS: Advances in genomics may eventually lead to genetic susceptibility screening of the general population, regardless of a personal or familial history of the disease in question. Yet, little is known about clinicians' attitudes toward such programs. We explored attitudes of family practitioners, medical geneticists and genetic counselors toward genetic screening of the general Ashkenazi-Jewish population for the common founder mutations in BRCA1/2 and LRRK2 genes (which increase the risk of hereditary breast/ovarian cancers and Parkinson's disease, respectively).
METHODS: Participants (n = 204) completed a specially designed questionnaire, distributed by e-mail, regular mail or in-person.
RESULTS: Slightly more than half (52%) were in favor of BRCA screening, while the vast majority (86%) opposed to LRRK2 screening. About two-thirds (68%) of the respondents supported pre-test genetic counseling. Attitudes were largely independent of professional background and sociodemographic characteristics, though a correlation was found with personal interest in genetic self-testing for the above genes. Adverse psychological impact and discrimination in insurance and employment were the major concerns cited by respondents with regard to screening programs.
CONCLUSION: Our findings suggest that the availability of measures for prevention and/or treatment is a major factor in the attitudes of healthcare providers toward population screening for late-onset conditions.
Copyright © 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23816973     DOI: 10.1159/000351592

Source DB:  PubMed          Journal:  Public Health Genomics        ISSN: 1662-4246            Impact factor:   2.000


  3 in total

1.  Physician and patient determinants of prognostic counseling in idiopathic REM sleep-behavior disorder.

Authors:  Max A Feinstein; Richard R Sharp; David J Sandness; John C Feemster; Mithri Junna; Suresh Kotagal; Melissa C Lipford; Maja Tippmann-Peikert; Bradley F Boeve; Michael H Silber; Erik K St Louis
Journal:  Sleep Med       Date:  2019-03-22       Impact factor: 3.492

2.  Population screening for BRCA1/BRCA2 mutations: lessons from qualitative analysis of the screening experience.

Authors:  Sari Lieberman; Amnon Lahad; Ariela Tomer; Carmit Cohen; Ephrat Levy-Lahad; Aviad Raz
Journal:  Genet Med       Date:  2016-12-01       Impact factor: 8.822

3.  Breast cancer in West Africa: molecular analysis of BRCA genes in early-onset breast cancer patients in Burkina Faso.

Authors:  Michela Biancolella; Nabonswindé Lamoussa Marie Ouédraogo; Nayi Zongo; Théodora Mahoukèdè Zohoncon; Barbara Testa; Barbara Rizzacasa; Andrea Latini; Chiara Conte; Tégwindé Rebeca Compaore; Charlemagne Marie Rayang-Newendé Ouedraogo; Si Simon Traore; Jacques Simpore; Giuseppe Novelli
Journal:  Hum Genomics       Date:  2021-10-30       Impact factor: 4.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.